NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
Clinical Trials
31 trialsNCT06943755 2026-02-27
STELLAR-311
Exelixis
Phase 2/3 Recruiting
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT03950609 2026-01-09
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT03049189 2025-05-30
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting
NCT01218555 2022-01-27
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Phase 1 Completed
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT02113800 2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03014297 2019-08-08
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
University of Kentucky
Phase 1 Terminated
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00688623 2019-01-25
RAMSETE/CDE16
Novartis
Phase 2 Completed
NCT01595009 2018-11-29
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
Novartis
Phase 4 Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT03629847 2018-08-14
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
King Faisal Specialist Hospital & Research Center
Phase 1/2 Unknown
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT01374451 2016-12-20
COOPERATE-2
Novartis
Phase 2 Terminated
NCT00804336 2016-10-19
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated
NCT01864070 2014-07-22
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed
NCT01338090 2012-04-03
NETPET
University Medical Center Groningen
Completed
NCT01175096 2010-08-04
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Guangdong Provincial People's Hospital
Phase 1/2 Unknown